CeloNova Reports Positive Results From Uterine Fibroid Embolization Study
Posted on: Monday, 21 January 2008, 06:00 CST
CeloNova BioSciences has reported positive data from the Sphere, an 11-center, eight-country European study of uterine fibroid embolization using the company's Embozene microspheres.
Patients in the study were followed for six months. The company said that technical success was achieved in 98% of the patients. The side effects of fibroids such as pain and heavy menstrual bleeding were significantly reduced while the patients' quality of life improved substantially.
Embolization is a minimally invasive procedure for uterine fibroids during which an interventional radiologist injects microspheres through a tiny catheter to the site of the fibroid. The microspheres block the blood flow to the fibroids causing them to atrophy.
Thomas Gordy, president and CEO, said: "From the beginning, CeloNova has operated on the principle that our products would give first-rate clinical outcomes for patients and meet the real-world needs of physicians. Color-coding improves patient safety while simplifying the job of those performing the procedure."
Source: Datamonitor
Related Articles
- Patient's Weight Not Linked To Success Of Fibroid Surgery
- Repros Therapeutics Inc. Announces That Proellex(R) Administered to Patients As Cyclic Therapy to Treat the Symptoms of Uterine Fibroids for Up to 30 Months Shows No Adverse Effects on the Endometrium
- Study Suggests Survival Benefit From Radioactive Microsphere Therapy in Patients With Colorectal Cancer Liver Metastases Who Have Failed Chemotherapy
- BioSphere Medical Highlights the Health and Practice Economic Benefits of Patient Loyalty and Retention Fostered When Discussing Treatment Options for Symptomatic Uterine Fibroids
- Sirtex Supports the Fourth Annual Clinical Symposium on Liver-Directed Microsphere Therapy Dedicated to Advancing Treatments for Patients With Inoperable Metastatic Liver Cancer
- Review Examines the Use of Sirtex's SIR-Spheres(R) Microspheres in Patients With Hepatic Colorectal Cancer Metastases
- Repeated Treatments of SIR-Spheres(R) Microspheres Appear to Be Safe for Patients With Metastatic Liver Tumors
- Landmark Study Evaluates Sirtex SIR-Spheres(R) Microspheres in Patients With Metastatic Liver Cancer
- One-Year Registry Data From 1,701 Women Shows High Rate of Significant Symptom Improvement and Patient Satisfaction With Non-Surgical Uterine Fibroid Embolization
- Interventional Radiologists Offer Liver Cancer Patients a Treatment Option With Nonsurgical Microspheres
 |
 |
User Comments (0)
RSS Feeds